Investigation of the clinical effects of hepatocellular carcinoma (HCC) treatment with human bone marrow (BM)-MSCs modified to overexpress IFN-α2b indicated the intervention caused delayed tumor growth in HepG2 cell-bearing NOD/SCID mouse through the negative regulation of the Notch signaling axis. This evidence concerns the gene IFNA2 and hepatocellular carcinoma.